Page 9 - Collective Coordinates News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Science 37 (NASDAQ:SNCE – Get Rating) and ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Analyst Recommendations This is a breakdown of current recommendations […]

/PRNewswire/ -- Argus Research, an independent investment research firm, has launched Argus Equity Report coverage on ProMIS Neurosciences, Inc. (TSX:PMN)...

MaxCyte (NASDAQ:MXCT – Get Rating) and ProMIS Neurosciences (OTCMKTS:ARFXF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends. Profitability This table compares MaxCyte and ProMIS Neurosciences’ net margins, […]

27.01.2022 - TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins ...